Taysha Gene Therapies (TSHA) Enterprise Value (2022 - 2025)
Historic Enterprise Value for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$297.8 million.
- Taysha Gene Therapies' Enterprise Value fell 8831.33% to -$297.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$297.8 million, marking a year-over-year decrease of 8831.33%. This contributed to the annual value of -$139.5 million for FY2024, which is 339.64% up from last year.
- According to the latest figures from Q3 2025, Taysha Gene Therapies' Enterprise Value is -$297.8 million, which was down 8831.33% from -$313.2 million recorded in Q2 2025.
- In the past 5 years, Taysha Gene Therapies' Enterprise Value ranged from a high of -$36.9 million in Q3 2022 and a low of -$313.2 million during Q2 2025
- Over the past 4 years, Taysha Gene Therapies' median Enterprise Value value was -$124.4 million (recorded in 2024), while the average stood at -$135.6 million.
- Over the last 5 years, Taysha Gene Therapies' Enterprise Value had its largest YoY gain of 3610.67% in 2023, and its largest YoY loss of 34467.96% in 2023.
- Taysha Gene Therapies' Enterprise Value (Quarter) stood at -$87.9 million in 2022, then crashed by 64.3% to -$144.4 million in 2023, then grew by 3.4% to -$139.5 million in 2024, then tumbled by 113.49% to -$297.8 million in 2025.
- Its Enterprise Value stands at -$297.8 million for Q3 2025, versus -$313.2 million for Q2 2025 and -$117.0 million for Q1 2025.